Anixa Biosciences, Inc. (ANIX) Stock Price & Analysis
Anixa Biosciences, Inc. (ANIX) closed at USD 2.78 on Thursday, October 15, 2026, up 4.71% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 2.66; the Oct 15, 2026 session ranged USD 2.63–2.79 on volume of 223,318 shares. Market capitalization is $96.64M, with a 52-week range of USD 2.32–5.46 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ANIX.md
Key facts (ANIX)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 9.75 (range 6–14).
- Total return with dividends: 1Y -36.8% vs S&P 500 +18.1%; 5Y -36.7% vs S&P 500 +85.1%.
- Next earnings: 2026-09-09, EPS estimate USD -0.08, revenue estimate $0K.
Analysts (ANIX)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 9.75 (low 6, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-22 | HC Wainwright & Co. | Target lowered | Buy | $7 → $6 |
Total return (dividends reinvested) (ANIX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -36.8% | -36.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -36.9% | -8.7% |
| Volatility (annualized) | 65.8% | 61.6% |
| Max drawdown | -55.0% (Dec 2025→Jun 2026) | -63.0% (Apr 2023→Jun 2024) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 2.78 |
|---|---|
| Change | ▲ 4.71% (up) |
| Previous Close | USD 2.66 |
| Open | USD 2.66 |
| Day Range | USD 2.63 – 2.79 |
| 52-Week Range | USD 2.32 – 5.46 |
| Volume | 223,318 shares |
| Market Cap | $96.64M |
| Exchange | NCM |
Technical Analysis (ANIX)
Nexqual's technical model rates ANIX "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.8 (neutral) |
| vs SMA50 | Below (USD 3.07) |
| MACD | -0.06 (negative) |
Analyst Ratings (ANIX)
Wall Street analysts rate ANIX "Buy" based on 4 analysts, with a mean price target of USD 9.75 (range USD 6–14), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 9.75 |
| High Target | USD 14 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (ANIX)
| Next Earnings Date | 2026-09-09 |
|---|---|
| EPS Estimate | USD -0.08 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-07-31 | USD -0.08 vs est -0.08 ▲ beat |
| 2026-04-30 | USD -0.07 vs est -0.1 ▲ beat |
| 2026-01-31 | USD -0.08 vs est -0.09 ▲ beat |
| 2025-10-31 | USD -0.09 vs est -0.09 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (ANIX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -73.17% |
| Debt / Equity | 0.01 |
| Current Ratio | 8.55 |
| Total Cash | $13.86M |
| Total Debt | $174,000 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (ANIX)
Nexqual rates Anixa Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $14M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M (TTM) |
| Efficiency | Critical — ROE -73%, ROA -41.9% |
Ownership (ANIX)
| Insider Ownership | +5.62% |
|---|---|
| Institutional Ownership | +13.88% |
| Shares Outstanding | 34.76M |
| Float | 32.81M |
| Short % of Float | +4.10% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (ANIX)
Anixa Biosciences, Inc. is led by Amit Kumar (age 61), CEO, Chairman & Co-Chair of CBAB, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO, Chairman & Co-Chair of CBAB | Amit Kumar (age 61) |
|---|---|
| President, COO, CFO & Corporate Secretary | Michael J. Catelani (age 58) |
Major Backers & Investors (ANIX)
Notable institutional backers of Anixa Biosciences, Inc. include UBS Group AG, Laird Norton Wetherby Trust Company, LLC, D.A. Davidson & Co., according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| UBS Group AG | 1.68% |
| Laird Norton Wetherby Trust Company, LLC | 1.66% |
| D.A. Davidson & Co. | 1.55% |
| Marshall Wace LLP | 0.94% |
| Fidelity | 0.75% |
| GSA Capital Partners LLP | 0.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.21% |
| Geode Capital | 1.03% |
| BlackRock | 0.88% |
| State Street | 0.46% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt